VECAMYL Tablet Ref.[10313] Active ingredients: Mecamylamine

Mecamylamine, a secondary amine, readily penetrates into the brain and thus may produce central nervous system effects. Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely. These have occurred most often when large doses of mecamylamine HCl were used, especially in patients with cerebral or renal insufficiency.

When ganglion blockers or other potent antihypertensive drugs are discontinued suddenly, hypertensive levels return. In patients with malignant hypertension and others, this may occur abruptly and may cause fatal cerebral vascular accidents or acute congestive heart failure. When mecamylamine HCl is withdrawn, this should be done gradually and other antihypertensive therapy usually must be substituted. On the other hand, the effects of mecamylamine HCl sometimes may last from hours to days after therapy is discontinued.

The following adverse reactions have been reported and within each category are listed in order of decreasing severity.

Gastrointestinal: Ileus, constipation (sometimes preceded by small, frequent liquid stools), vomiting, nausea, anorexia, glossitis and dryness of mouth.

Cardiovascular: Orthostatic dizziness and syncope, postural hypotension.

Nervous System/Psychiatric: Convulsions, choreiform movements, mental aberrations, tremor, and paresthesias (see WARNINGS).

Respiratory: Interstitial pulmonary edema and fibrosis.

Urogenital: Urinary retention, impotence, decreased libido.

Special Senses: Blurred vision, dilated pupils.

Miscellaneous: Weakness, fatigue, sedation.

The patient’s condition should be evaluated carefully, particularly as to renal and cardiovascular function. When renal, cerebral, or coronary blood flow is deficient, any additional impairment, which might result from added hypotension, must be avoided. The use of mecamylamine HCl in patients with marked cerebral and coronary arteriosclerosis or after a recent cerebral accident requires caution.

The action of mecamylamine HCl may be potentiated by excessive heat, fever, infection, hemorrhage, pregnancy, anesthesia, surgery, vigorous exercise, other antihypertensive drugs, alcohol, and salt depletion as a result of diminished intake or increased excretion due to diarrhea, vomiting, excessive sweating, or diuretics.

During therapy with mecamylamine HCl, sodium intake should not be restricted but, if necessary, the dosage of the ganglion blocker must be adjusted.

Since urinary retention may occur in patients on ganglion blockers, caution is required in patients with prostatic hypertrophy, bladder neck obstruction, and urethral stricture.

Frequent loose bowel movements with abdominal distention and decreased borborygmi may be the first signs of paralytic ileus. If these are present, mecamylamine HCl should be discontinued immediately and remedial steps taken.

Mecamylamine HCl may cause dizziness, lightheadedness, or fainting, especially when rising from a lying or sitting position. This effect may be increased by alcoholic beverages, exercise, or during hot weather. Getting up slowly may help alleviate such a reaction.

Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.

The action of mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol.

Pregnancy Category C.

Animal reproduction studies have not been conducted with mecamylamine HCl. It is not known whether mecamylamine HCl can cause fetal harm when given to a pregnant woman or can affect reproductive capacity. Mecamylamine HCl should be given to a pregnant woman only if clearly needed.

Because of the potential for serious adverse reactions in nursing infants from mecamylamine HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in pediatric patients have not been established.